Show Summary Details
Page of

Colon cancer 

Colon cancer
Colon cancer

Debashis Biswas

and Thankamma Ajithkumar

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2021

Significant progress has been made in the management of colon cancer in the last decade. Improvements in surgical techniques have had a major impact on the survival. Adjuvant fluoropyrimidine chemotherapy has improved survival, especially in stage III disease. The addition of oxalipatin to fluoroprimidines improves survival further, especially in stage III patients aged less than 65 years. However, the addition of oxaliplatin should be carefully balanced against predicted tolerability and toxicity. Close postoperative follow-up helps to identify potentially radically treatable oligometastatic recurrences. Integration of targeted therapy with chemotherapy results in improvement in survival in metastatic disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.